Amgen Inc - Company Snapshot & SWOT Analysis
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. The company has a presence in approx. 100 countries worldwide. Amgen operates in one business segment: human therapeutics.
Amgen reported revenue of USD 23.747 billion for the FY 2018 which saw an increase of 3.93% compared to FY 2017. This revenue is expected to decrease by 3.57% and reach USD 22.90 billion by FY 2019 due to loss of patent and price erosion of key drugs. Amgen revenue grew at a CAGR of 4.92% during FY 2013 to FY 2018.
Amgen registered the highest revenue from the United States market at USD 18.358 billion which accounted for 77.31% of its total revenue in FY 2018.
Scope of the Amgen Inc. - Company Snapshot & SWOT Analysis Report
Amgen reported revenue of USD 23.747 billion for the FY 2018 which saw an increase of 3.93% compared to FY 2017. This revenue is expected to decrease by 3.57% and reach USD 22.90 billion by FY 2019 due to loss of patent and price erosion of key drugs. Amgen revenue grew at a CAGR of 4.92% during FY 2013 to FY 2018.
Amgen registered the highest revenue from the United States market at USD 18.358 billion which accounted for 77.31% of its total revenue in FY 2018.
Scope of the Amgen Inc. - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Amgen Inc including value chain analysis, financial performance, business strategy, and SWOT analysis.
- The report identifies the growth drivers and inhibitors for the global pharmaceutical market.
- This report provides information about current and future trends for the global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Amgen Inc. - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Amgen Inc.
3.1.1 Company Profile
3.1.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Amgen Inc: Financial Performance
3.1.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
3.1.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion) 15
3.1.4 Amgen Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
Scope of the Amgen Inc. - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Amgen Inc.
3.1.1 Company Profile
3.1.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Amgen Inc: Financial Performance
3.1.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
3.1.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion) 15
3.1.4 Amgen Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key information of Amgen Inc.
Exhibit 3.2 Contact details of Amgen Inc.
Exhibit 3.3 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 3.4 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.7 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.8 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 3.9 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.10 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 3.11 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.12 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 3.13 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 3.14 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.15 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.16 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.17 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 3.18 SWOT Analysis of Amgen Inc.
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key information of Amgen Inc.
Exhibit 3.2 Contact details of Amgen Inc.
Exhibit 3.3 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 3.4 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.7 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.8 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 3.9 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.10 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 3.11 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.12 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 3.13 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 3.14 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 3.15 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.16 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 3.17 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 3.18 SWOT Analysis of Amgen Inc.
